The global graft versus host disease (GvHD) treatment market size was estimated to be USD 2.84 billion in 2023 and is expected to reach USD 6.78 billion by 2034 with a CAGR of 8.23% during the forecast period 2024-2034. The market will rise as a result of factors such as the increasing prevalence of GvHD, improvements in transplant techniques, the growing need for novel therapies, increased awareness and better diagnosis, expanding government initiatives, and partnerships and collaborations.
The market for GvHD treatments is mostly driven by the rising number of people receiving allogeneic hematopoietic stem cell transplantation (HSCT). HSCT is a process that uses donor-healthy stem cells to replace damaged or diseased bone marrow. GvHD is a dangerous side effect that can happen following HSCT, where the recipient's body is attacked by the immune system of the donor. Leukemia and lymphoma are two blood diseases that are becoming more common. This is also leading to an increase in HSCT operations and, as a result, in cases of GvHD. For instance, the total number of transplants carried out in the US between January 2022 and June 2022 was 20,663, according to data updated in July 2022 by the Organ Procurement and Transplantation Network, which is run by the US Department of Health and Human Services.
By disease type, the chronic graft-versus-host disease (cGvHD) segment accounted for the highest revenue-grossing segment in the global graft versus host disease (GvHD) treatment market in 2023 owing to the increasing prevalence of cGvHD cases, advancements in targeted therapies, and rising awareness among healthcare professionals and patients about the need for effective and long-term treatment options. For instance, the European Commission (EC) approved Novartis' Jakavi (ruxolitinib) in May 2022 for the treatment of patients with acute or chronic GvHD who are 12 years of age or older who do not respond well to corticosteroids or other systemic medications. Additionally, the acute graft-versus-host disease (aGvHD) segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of stem cell transplants, advancements in early diagnosis and treatment approaches, and increasing research initiatives focused on developing novel therapies for acute GvHD.
By product, the corticosteroids segment accounted for the highest revenue-grossing segment in the global graft versus host disease (GvHD) treatment market in 2023 owing to the established efficacy, widespread clinical use, and the ability to manage inflammation and immune response, making corticosteroids a primary choice for treating GvHD across various patient populations. For instance, Novartis and Pfizer are working together to develop PF-06823025, a JAK1 inhibitor, to treat acute and chronic GvHD that is resistant to steroids. Additionally, the JAK inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing understanding of their immunosuppressive properties, ongoing clinical trials demonstrating their efficacy, and the increasing adoption of JAK inhibitors as a targeted and promising therapeutic option for graft-versus-host disease (GvHD) treatment.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global graft versus host disease (GvHD) treatment market in 2023 owing to the prevalence of severe cases requiring specialized medical supervision, the availability of a wide range of GvHD treatments in hospital settings, and the preference for inpatient care for complex and intensive treatment regimens. For instance, in January 2023, Pfizer acquired Seagen Inc., an organization that had been creating cutting-edge cancer medicines. Pfizer's position in the GvHD market is strengthened by this acquisition, as Seagen is developing multiple possible medicines. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital healthcare platforms, rising patient preference for convenience, and the expansion of online pharmacy services, providing easier access to a diverse range of graft-versus-host disease (GvHD) treatments for a broader patient population.
North American region is anticipated to have the highest revenue share during the forecast period owing to the established healthcare infrastructure, high prevalence of hematologic disorders necessitating GvHD treatment, and early adoption of advanced therapies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness about GvHD, rising healthcare investments, a growing patient pool, and advancements in medical research and infrastructure. For instance, Equillium Inc. started the pivotal Phase III clinical research of itolizumab in patients with acute graft-versus-host disease (aGvHD) in March 2022. As a first-line treatment for aGvHD in conjunction with corticosteroids, the randomized, double-blind study will evaluate the safety and effectiveness of itolizumab versus placebo.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The market for GvHD treatments is mostly driven by the rising number of people receiving allogeneic hematopoietic stem cell transplantation (HSCT). HSCT is a process that uses donor-healthy stem cells to replace damaged or diseased bone marrow. GvHD is a dangerous side effect that can happen following HSCT, where the recipient's body is attacked by the immune system of the donor. Leukemia and lymphoma are two blood diseases that are becoming more common. This is also leading to an increase in HSCT operations and, as a result, in cases of GvHD. For instance, the total number of transplants carried out in the US between January 2022 and June 2022 was 20,663, according to data updated in July 2022 by the Organ Procurement and Transplantation Network, which is run by the US Department of Health and Human Services.
By disease type, the chronic graft-versus-host disease (cGvHD) segment accounted for the highest revenue-grossing segment in the global graft versus host disease (GvHD) treatment market in 2023 owing to the increasing prevalence of cGvHD cases, advancements in targeted therapies, and rising awareness among healthcare professionals and patients about the need for effective and long-term treatment options. For instance, the European Commission (EC) approved Novartis' Jakavi (ruxolitinib) in May 2022 for the treatment of patients with acute or chronic GvHD who are 12 years of age or older who do not respond well to corticosteroids or other systemic medications. Additionally, the acute graft-versus-host disease (aGvHD) segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of stem cell transplants, advancements in early diagnosis and treatment approaches, and increasing research initiatives focused on developing novel therapies for acute GvHD.
By product, the corticosteroids segment accounted for the highest revenue-grossing segment in the global graft versus host disease (GvHD) treatment market in 2023 owing to the established efficacy, widespread clinical use, and the ability to manage inflammation and immune response, making corticosteroids a primary choice for treating GvHD across various patient populations. For instance, Novartis and Pfizer are working together to develop PF-06823025, a JAK1 inhibitor, to treat acute and chronic GvHD that is resistant to steroids. Additionally, the JAK inhibitors segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing understanding of their immunosuppressive properties, ongoing clinical trials demonstrating their efficacy, and the increasing adoption of JAK inhibitors as a targeted and promising therapeutic option for graft-versus-host disease (GvHD) treatment.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global graft versus host disease (GvHD) treatment market in 2023 owing to the prevalence of severe cases requiring specialized medical supervision, the availability of a wide range of GvHD treatments in hospital settings, and the preference for inpatient care for complex and intensive treatment regimens. For instance, in January 2023, Pfizer acquired Seagen Inc., an organization that had been creating cutting-edge cancer medicines. Pfizer's position in the GvHD market is strengthened by this acquisition, as Seagen is developing multiple possible medicines. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital healthcare platforms, rising patient preference for convenience, and the expansion of online pharmacy services, providing easier access to a diverse range of graft-versus-host disease (GvHD) treatments for a broader patient population.
North American region is anticipated to have the highest revenue share during the forecast period owing to the established healthcare infrastructure, high prevalence of hematologic disorders necessitating GvHD treatment, and early adoption of advanced therapies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing awareness about GvHD, rising healthcare investments, a growing patient pool, and advancements in medical research and infrastructure. For instance, Equillium Inc. started the pivotal Phase III clinical research of itolizumab in patients with acute graft-versus-host disease (aGvHD) in March 2022. As a first-line treatment for aGvHD in conjunction with corticosteroids, the randomized, double-blind study will evaluate the safety and effectiveness of itolizumab versus placebo.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Disease Type, Product, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Graft Versus Host Disease (GvHD) Treatment Market Report 2023 - 2034
Graft Versus Host Disease (GvHD) Treatment Market Analysis & Forecast by Disease Type 2023 - 2034 (Revenue USD Bn)
- Acute Graft-versus-Host Disease
- Chronic Graft-versus-Host Disease
Graft Versus Host Disease (GvHD) Treatment Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Corticosteroids
- TNFα Inhibitors
- Immunosuppressants
- ATG Therapies
- mTOR Inhibitors
- SOT Therapy
- Calcineurin Inhibitors
- Monoclonal antibodies
- Tyrosine kinase inhibitors
- Other Products
Graft Versus Host Disease (GvHD) Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Graft Versus Host Disease (GvHD) Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Graft Versus Host Disease (GvHD) Treatment Market: Disease Type Estimates & Trend Analysis
8. Graft Versus Host Disease (GvHD) Treatment Market: Product Estimates & Trend Analysis
9. Graft Versus Host Disease (GvHD) Treatment Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Graft Versus Host Disease (GvHD) Treatment Market
12. Europe Graft Versus Host Disease (GvHD) Treatment Market
13. Asia Pacific Graft Versus Host Disease (GvHD) Treatment Market
14. Latin America Graft Versus Host Disease (GvHD) Treatment Market
15. MEA Graft Versus Host Disease (GvHD) Treatment Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Novartis AG
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd. (Roche)
- Bristol Myers Squibb (BMS)
- Merck & Co. Inc.
- Jazz Pharmaceuticals
- Takeda Pharmaceutical Company Limited
- Sanofi
- Mallinckrodt Pharmaceuticals
- Kiadis Pharma.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 2.84 Billion |
| Forecasted Market Value ( USD | $ 6.78 Billion |
| Compound Annual Growth Rate | 8.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
